State-of-the-art strategies for targeting the DNA damage response in cancer

PG Pilié, C Tang, GB Mills, TA Yap - Nature reviews Clinical oncology, 2019 - nature.com
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

B Cheng, W Pan, Y Xing, Y Xiao, J Chen… - European Journal of …, 2022 - Elsevier
DDR (DNA damage response) defects in cells drive tumor formation by promoting DNA
mutations, which also provides cancer-specific vulnerabilities that can be targeted by …

Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent

KM Foote, JWM Nissink, T McGuire, P Turner… - 2018 - ACS Publications
The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the
DNA-damage response and the apical kinase which orchestrates the cellular processes that …

ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib

Z Wilson, R Odedra, Y Wallez, PWG Wijnhoven… - Cancer research, 2022 - AACR
AZD6738 (ceralasertib) is a potent and selective orally bioavailable inhibitor of ataxia
telangiectasia and Rad3-related (ATR) kinase. ATR is activated in response to stalled DNA …

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

A Bradbury, S Hall, N Curtin, Y Drew - Pharmacology & therapeutics, 2020 - Elsevier
The DNA damage response (DDR) machinery is responsible for detecting DNA damage,
pausing the cell cycle and initiating DNA repair. Ataxia telangiectasia and Rad3-related …

Hydrogen sulfide biology and its role in cancer

S Khattak, MA Rauf, NH Khan, QQ Zhang, HJ Chen… - Molecules, 2022 - mdpi.com
Hydrogen sulfide (H2S) is an endogenous biologically active gas produced in mammalian
tissues. It plays a very critical role in many pathophysiological processes in the body. It can …

Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand

L Mei, J Zhang, K He, J Zhang - Journal of hematology & oncology, 2019 - Springer
Background The ataxia telangiectasia and Rad3-related (ATR) checkpoint kinase 1 (CHK1)
pathway plays an essential role in suppressing replication stress from DNA damage and …

ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy

M Wang, X Ran, W Leung, A Kawale… - Genes & …, 2023 - genesdev.cshlp.org
The mismatch repair (MMR) deficiency of cancer cells drives mutagenesis and offers a
useful biomarker for immunotherapy. However, many MMR-deficient (MMR-d) tumors do not …

An overview of the recent development of anticancer agents targeting the HIF-1 transcription factor

Y Shirai, CCT Chow, G Kambe, T Suwa, M Kobayashi… - Cancers, 2021 - mdpi.com
Simple Summary As hypoxia-inducible factor 1 (HIF-1) is recognized as a target for cancer
therapy, extensive efforts have been devoted to developing its inhibitors. We provide an …

ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer

H Taniguchi, S Chakraborty, N Takahashi… - Science …, 2024 - science.org
Patients with small-cell lung cancer (SCLC) have poor prognosis and typically experience
only transient benefits from combined immune checkpoint blockade (ICB) and …